HAYWARD, Calif., Nov 4, 2003 (BUSINESS WIRE) -- IMPAX
Laboratories, Inc. (Nasdaq:IPXL) today announced that management will
present at the CIBC World Markets 14th Annual Healthcare Conference on
Wednesday, November 12, 2003, at 2:30 p.m. ET. The conference will
take place at the Plaza Hotel in New York from November 10 to November
12, 2003.
Individuals may listen to both the live and archived webcast of
the presentation through Friday, December 12, 2003, at 8:00 p.m. ET,
at the following address:
www.veracast.com/webcasts/cibcwm/healthcare03/47312258.cfm. In
addition, a link to the live and archived presentation will be posted
in the investor relations section of the Company's web site at
www.impaxlabs.com.
IMPAX Laboratories, Inc. is a technology based specialty
pharmaceutical company applying its formulation expertise and drug
delivery technology to the development of controlled-release and
specialty generics in addition to the development of branded products.
IMPAX markets its generic products through its Global Pharmaceuticals
division and intends to market its branded products through the IMPAX
Pharmaceuticals division. Additionally, where strategically
appropriate, IMPAX has developed marketing partnerships to fully
leverage its technology platform. IMPAX Laboratories is headquartered
in Hayward, California, and has a full range of capabilities in its
Hayward and Philadelphia facilities. For more information, please
visit the Company's Web site at: www.impaxlabs.com.
"Safe Harbor" statement under the Private Securities Litigation
Reform Act of 1995:
To the extent any statements made in this news release contain
information that is not historical, these statements are
forward-looking in nature and express the beliefs, expectations or
opinions of management. Such statements are based on current
expectations and involve a number of known and unknown risks and
uncertainties that could cause IMPAX's future results, performance or
achievements to differ significantly from the results, performance or
achievements expressed or implied by such forward-looking statements.
Such risks and uncertainties include, but are not limited to, IMPAX's
ability to obtain sufficient capital to fund its operations, the
difficulty of predicting FDA filings and approvals, consumer
acceptance and demand for new pharmaceutical products, the impact of
competitive products and pricing, IMPAX's ability to successfully
develop and commercialize pharmaceutical products, IMPAX's reliance on
key strategic alliances, the uncertainty of patent litigation, the
availability of raw materials, the regulatory environment, dependence
on patent and other protection for innovative products, exposure to
product liability claims, fluctuations in operating results and other
risks detailed from time to time in IMPAX's filings with the
Securities and Exchange Commission. Forward-looking statements speak
only as to the date on which they are made, and IMPAX undertakes no
obligation to update publicly or revise any forward-looking statement,
regardless of whether new information becomes available, future
developments occur or otherwise.
SOURCE: IMPAX Laboratories, Inc.
IMPAX Laboratories, Inc.
Barry R. Edwards, Co-CEO, 215-289-2220 Ext. 1771
Larry Hsu, Ph.D. President, 510-476-2000 Ext. 1111
Cornel C. Spiegler, CFO, 215-289-2220 Ext. 1706
www.impaxlabs.com
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz (kgolodetz@lhai.com)
212-838-3777
Bruce Voss (bvoss@lhai.com)
310-691-7100
www.lhai.com
Customize your Business Wire news & multimedia to match your needs.
Get breaking news from companies and organizations worldwide.
Logon for FREE today at www.BusinessWire.com.